PHAXIAM Therapeutics S.A. Overview
PHAXIAM Therapeutics S.A. (PHXM) has a P/E ratio of -0.02, below the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow-0.02
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
PHAXIAM Therapeutics S.A. (PHXM) currently reports a P/E ratio of -0.02. That is below the Healthcare sector average of 26.36. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s P/E ratio history and peer comparisons.
PHAXIAM Therapeutics S.A.'s P/E ratio of -0.02 is lower than the Healthcare sector average of 26.36. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates PHAXIAM Therapeutics S.A.'s market price to a fundamental measure such as earnings, sales, or book value. At -0.02, PHXM can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.02, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.
PHAXIAM Therapeutics S.A. is classified in the Healthcare sector. On P/E ratio, it currently shows -0.02 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHXM with unrelated industries.
